Bupivacaine is contraindicated for IV regional anaesthesia (IVRA) because of potential risk of tourniquet failure and systemic absorption of the drug. This chemical is a kind of bulk pharmaceutical chemical. There are some basic informations about this crude drug: (1)CAS number: ; (2)ATC code: N01BB01; (3)PubChem: CID 5282419; (4)ChemSpider: 4445574; (5)Formula: C₁₈H₂₈N₂O; (6)Mol. mass: 288.43 g/mol.

Bupivacaine is a local anaesthetic drug belonging to the amino amide group. AstraZeneca commonly markets it under various trade names, including Marcain, Marcaine, Sensorcaine and Vivacaine. Bupivacaine is indicated for local anaesthesia including infiltration, nerve block, epidural, and intrathecal anaesthesia. Bupivacaine often is administered by epidural injection before total hip arthroplasty. It also is commonly injected to surgical wound sites to reduce pain for up to 20 hours after the surgery. Sometimes, bupivacaine is co-administered with epinephrine to prolong the duration of its action, fentanyl for epidural analgesia, or glucose.